发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
The Big Take How Eli Lilly Got Huge By Making Us Thin Dave Ricks steered the 150-year-old drug giant to a $1 trillion market cap. Can he defeat pharma’s boom and bust cycle?
发布时间
108 天前
2026-06-22 15:30:19 UTC
源站更新
108 天前
2026-06-22 15:30:19 UTC
首次抓取
108 天前
2026-06-22 19:41:27 UTC
礼来在 CEO 戴夫·里克斯推动下，凭借减重和糖尿病药物 Mounjaro、Zepbound 跻身万亿美元市值公司，并借提速研发、扩产和直面消费者策略反超竞争对手。如今公司仍面临专利周期、价格压力、竞争加剧和内部文化紧张等考验。
Under CEO Dave Ricks, Eli Lilly rode blockbuster diabetes and obesity drugs including Mounjaro and Zepbound to a $1 trillion valuation, helped by faster R&D, manufacturing expansion and direct-to-consumer sales. The bigger test now is sustaining that lead amid patent risks,
用于追踪这条内容的来源与记录标识。
